Atorvastatin prevented and partially reversed adrenocorticotropic hormone-induced hypertension in the rat

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 4, 2006, Pages 369-373

  Mondo, Charles K ^a   Yang, Wan Song ^a   Su, Ji Zhou ^a   Huang, Ti Gang ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Adrenocorticotropic hormone; Atorvastatin; Blood pressure; Rat

Indexed keywords

ATORVASTATIN; CORTICOTROPIN; DRINKING WATER; NITRATE; NITRITE; SODIUM CHLORIDE; SUPEROXIDE; TAP WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DRUG EFFECT; HYPERTENSION; MALE; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; NITRIC OXIDE; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDES;

EID: 33645038657     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04377.x     Document Type: Article

References (34)

1. Turner SW Wen C Li M Fraser TB Whitworth JA Adrenocorticotrophin dose-response relationships in the rat: Haemodynamic, metabolic and hormonal effects JHypertens 1998 16 593 600
2. Turner SW Wen C Li M Whitworth JA l -arginine prevents corticotropin-induced increases in blood pressure in the rat Hypertension 1996 27 184 9
3. Wen C Fraser T Li M Whitworth JA Hemodynamic profile of corticotropin-induced hypertension in the rat JHypertens 1998 16 187 94
4. Wen C Li M Fraser T Wang J Turner SW Whitworth JA l -arginine partially reverses established adrenocorticotrophin-induced hypertension and nitric oxide deficiency in the rat Blood Press 2000 9 298 304
5. Hattori Y Akimoto K Nakanishi N Kasai K Glucocorticoid regulation of nitric oxide and tetrahydrobiopterin in a rat model of endotoxic shock BiochemBiophysResCommun 1997 240 298 303
6. Wallerath T Witte K Schafer SC et al. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension ProcNatl AcadSciUSA 1999 96 13 357 62
7. Lou YK Wen C Li M et al. Decreased renal expression of nitric oxide synthase isoforms in adrenocorticotropin-induced and corticosterone-induced hypertension Hypertension 2001 37 1164 70
8. Zhang Y Jang R Mori TA et al. The anti-oxidant Tempol reverses and partially prevents adrenocorticotrophic hormone-induced hypertension in the rat JHypertens 2003 21 1513 18
9. Zhang Y Croft KD Mori TA Schyvens CG McKenzie KU Whitworth JA The antioxidant tempol prevents and partially reverses dexamethasone-induced hypertension in the rat AmJHypertens 2004 17 260 5
10. Pechanova O Zicha J Kojsova S Dobesova Z Jendekova L Kunes J The effect of chronic N-acetylcysteine treatment on the development of spontaneous hypertension ClinSci(Lond.) 2005
11. Landmesser U Harrison DG Drexler H Oxidant stress-a major cause of reduced endothelial nitric oxide availability in cardiovascular disease EurJClinPharmacol 2005 1 7
12. Wilcox CS Oxidative stress and nitric oxide deficiency in the kidney: A critical link to hypertension? AmJPhysiolRegulIntegrCompPhysiol 2005 289 R913 35
13. Ray R Shah AM NADPH oxidase and endothelial cell function ClinSci(Lond.) 2005 109 217 26
14. Manning Jr. RD Tian N Meng S Oxidative stress and antioxidant treatment in hypertension and the associated renal damage AmJNephrol 2005 25 311 17
15. Drummond GA ASCOT-LLA: questions about the benefits of atorvastatin Lancet 2003 361 1987 8
16. Osende JI Ruiz-Ortega M Blanco-Colio LM Egido J Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study NephrolDial. Transplant 2004 19 528 31
17. Nambi V Ballantyne CM ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients CurrAtheroscler. Rep 2004 6 353 8
18. Sever PS Dahlof B Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial Drugs 2004 64 Suppl. 2 43 60
19. Blanco-Colio LM Osende JI Martin-Ventura JL Tunon J Egido J Statins in hypertensive patients: Potential explanations for the ASCOT-LLA study results Drugs 2004 64 61 7
20. Neau JP Moumy H Mathis S Gil R [Statins and prevention of strokes] RevNeurol(Paris) 2005 161 237 44
21. Tayek J Atorvastatin reduced coronary and stroke events in patients with hypertension and without dyslipidemia ACP JClub 2004 140 A16 author reply A
22. Vaughan CM Murphy Buckley B Statins do more than just lower cholesterol Lancet 1996 348 1079 82
23. Moshage H Kok B Huizenga JR Jansen PL Nitrite and nitrate determinations in plasma: A critical evaluation ClinChem 1995 41 892 6
24. Beswick RA Zhang H Marable D Catravas JD Hill WD Webb RC Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response Hypertension 2001 37 781 6
25. Nishiyama A Fukui T Fujisawa Y et al. Systemic and regional hemodynamic responses to tempol in angiotensin II-infused hypertensive rats Hypertension 2001 37 77 83
26. Vaziri ND Ni Z Oveisi F Liang K Pandian R Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency Hypertension 2002 39 135 41
27. Kissner R Nauser T Bugnon P Lye PG Koppenol WH Formation and properties of peroxynitrite as studied by laser flash photolysis, high-pressure stopped-flow technique, and pulse radiolysis ChemResToxicol 1997 10 1285 92
28. Zhou MS Jaimes EA Raij L Atorvastatin prevents end-organ injury in salt-sensitive hypertension: Role of eNOS and oxidant stress Hypertension 2004 44 186 90
29. Wassmann S Laufs U Baumer AT et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species Hypertension 2001 37 1450 7
30. Griendling KK Minieri CA Ollerenshaw JD Alexander RW Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells CircRes 1994 74 1141 8
31. Higashi M Shimokawa H Hattori T et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: Effect on endothelial NAD (P) H oxidase system CircRes 2003 93 767 75
32. Menschikowski M Hagelgans A Heyne B et al. Statins potentiate the IFN-gamma-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells BiochimBiophysActa 2005 1733 157 71
33. Senokuchi T Matsumura T Sakai M et al. Statins suppress oxidized low density lipoprotein-induced macrophage proliferation by inactivation of the small G protein-p38 MAPK pathway JBiolChem 2005 280 6627 33
34. Tramontano AF O'Leary J Black AD Muniyappa R Cutaia MV El-Sherif N Statin decreases endothelial microparticle release from human coronary artery endothelial cells: Implication for the Rho-kinase pathway BiochemBiophysResCommun 2004 320 34 8